Jinan Hongyuan Chemical Co.,Ltd
86-13954187575
As of now, the cumulative number of COVID-19 infections worldwide has exceeded 187 million, and about 4 million have died (Figure 1). Although relevant vaccines hav
Recently, Hengrui Medicine's Class 1 new drug SHR3680 combined with androgen deprivation therapy (ADT) compared to standard the
In 10 years, the situation is changing, and the pharmaceutical field will also undergo significant changes. In particular, a batch of super "blockbusters" will fall
Overview of Lung Cancer (1) Definition of lung cancer
In the first half of 2021, due to the impact of the new crown epidemic in some regions, pharmaceutical companies such as medica
Yaozhi data shows that in this period (July 2 to July 9), 27 new drugs were approved clinically (40 acceptance numbers); another 39 varieties (60 acceptance numbers
July 9, 2021, San Francisco, USA and Suzhou, China-Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated
一. In the first half of 2021, the overall situation of drug registration applications
On July 2, the Drug Evaluation Center of the National Medical Products Administration issued a notice for publicly soliciting o
On July 2, 2021, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Guiding Princ
Patent right is an intangible property right, and the essence of the patent system is to protect innovation. With the evolution of the international and domestic ec
On June 29, 2021, Zhuhai United Laboratories Co., Ltd. announced that it had received the Notice of Acceptance of Clinical Registration Application for Semaglutide Injection (Semaglutide Injection) is
On July 2, 2021, Kangfang Bio-Bio announced that the PD-1 monoclonal antibody drug Paimrizumab (R&D code: AK105, trad
Recently, the national first-class confidential Chinese medicine Pill Zihuang's value has skyrocketed, with an ex-factory price of 590 yuan. E-commerce platforms ge
Just now, Shanghai Sunshine Pharmaceutical Purchasing Network announced the results of the
Since 2016, the country has negotiated drug prices every year, and 5 rounds of medical insurance negotiations have been conducted. The first round of medical
Highlights: 1. 37 new drugs obtained implied approval for clin
The fifth batch of national procurement with volume (hereinafter referred to as "this national procurement") was carried out in Shanghai the d
The latest news on June 17th, Shanghai Heyu Biomedical Technology Co., Ltd. submitted a prospectus to the Hong Kong Stock Exchange on the even
On June 7, Corning Jerry, the global leader in the development of PD-(L)1/CTLA-4 dual antibodies, announced PD-L1/CTLA-4 in the form of
After the early collection of coronary stents and the upcoming blowout of orthopedic consumables, the market’s "favor and favor for de
A few days ago, at a press conference held by the Joint Prevention and Control Mechanism of the State Council, a reporter had just asked about
Since 2015, the global gene therapy industry has accelerated its development and continued to make breakthroughs. Especially after 2017, with
On June 10, according to the official website of the National Medical Products Administration (NMPA) of China, Bristol-Myers Squibb's immune c
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
